Reduced ALK-5 and TGFBR2 expression correlates with a shorter survival rate of colon cancer patients, as does reduced expression of the coreceptor betaglycan in breast and prostate cancer patients [48–50]. This evidence concerns the gene TGFBR2 and malignant colon neoplasm.